Mirati Therapeutics, Inc. - News Releases

2019 2018 2017 2016 2015 2014 2013

12/09/2013

Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS

12/02/2013

Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

11/22/2013

Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

11/12/2013

Mirati Therapeutics Reports Third Quarter 2013 Financial Results

11/08/2013

Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting

10/23/2013

Mirati Therapeutics Prices Public Offering Of Common Stock

10/16/2013

Mirati Therapeutics Announces Public Offering Of Common Stock

9/04/2013

Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors

8/12/2013

Mirati Therapeutics Reports Second Quarter 2013 Financial Results

7/19/2013

Mirati Therapeutics to Voluntarily Delist from TSX

7/15/2013

Mirati Therapeutics to Commence Trading on the NASDAQ

6/28/2013

Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement

5/09/2013

MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ